Trading Report: The Emerald Advisers Inc. PA Takes Position in Sarepta Therapeutics Inc. (SRPT)

The Emerald Advisers Inc. PA Takes Position in Sarepta Therapeutics Inc. (SRPT)

Emerald Advisers Inc. PA acquired a new stake in shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) during the second quarter, Holdings Channel reports. The fund acquired 235,506 shares of the company’s stock, valued at approximately $4,491,000.

Several other large investors also recently added to or reduced their stakes in the stock. State Street Corp boosted its stake in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares during the last quarter. Franklin Resources Inc. bought a new stake in Sarepta Therapeutics during the first quarter valued at about $13,506,000. A.R.T. Advisors LLC bought a new stake in Sarepta Therapeutics during the first quarter valued at about $7,461,000. Eagle Asset Management Inc. bought a new stake in Sarepta Therapeutics during the second quarter valued at about $6,756,000. Finally, Emerald Mutual Fund Advisers Trust bought a new stake in Sarepta Therapeutics during the second quarter valued at about $4,712,000. Hedge funds and other institutional investors own 65.29% of the company’s stock.

Sarepta Therapeutics Inc. (NASDAQ:SRPT) traded down 6.24% during mid-day trading on Friday, reaching $57.89. 8,985,494 shares of the company were exchanged. Sarepta Therapeutics Inc. has a 1-year low of $8.00 and a 1-year high of $63.73. The stock’s market capitalization is $2.77 billion. The stock’s 50-day moving average price is $40.98 and its 200-day moving average price is $25.39.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter in the prior year, the firm posted ($0.87) earnings per share. On average, equities research analysts anticipate that Sarepta Therapeutics Inc. will post ($4.23) EPS for the current fiscal year.

Several equities research analysts recently weighed in on the stock. Leerink Swann upgraded shares of Sarepta Therapeutics from an “underperform” rating to a “market perform” rating and set a $50.00 price target on the stock in a research report on Monday, September 19th. Piper Jaffray Cos. upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Monday, September 19th. Janney Montgomery Scott set a $30.00 price target on shares of Sarepta Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, August 3rd. William Blair upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 price target on the stock in a research report on Monday, September 19th. Finally, Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, July 19th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $58.12.

In other Sarepta Therapeutics news, VP Jayant Aphale sold 35,000 shares of the firm’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,750,000.00. Following the completion of the sale, the vice president now directly owns 21,490 shares of the company’s stock, valued at approximately $1,074,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the sale, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is owned by company insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Related posts

Leave a Comment